BOTA News Alert Biota Pharmaceuticals Inc (BOTA) 2.26 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biota Pharmaceuticals Inc (BOTA) 2.26 $BOTA

Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xw7rg5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - ConjuGon, Inc. - Omnia Molecular Ltd. - ContraFect Corporation - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xw...terococcus
BOTA: 2.26 (unch)

Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST

LOXO: 13.50 (+0.06), TRGT: 2.73 (+0.08), BOTA: 2.26 (unch), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BIOS: 6.37 (unch), RGDO: 0.89 (unch), EXEL: 1.29 (-0.01), AMPH: 11.74 (-0.09)

Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced its financial results for the three month period ended September 30, 2014, which is the first quarter of the Company's 2015 fiscal year, and provided an update on recent corporate developments.
BOTA: 2.26 (unch)

Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2014
GlobeNewswire - Tue Oct 28, 4:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
BOTA: 2.26 (unch)

3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.91 (+0.36), BOTA: 2.26 (unch), RGDO: 0.89 (unch)

Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Sep 26, 6:01AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent corporate developments.
BOTA: 2.26 (unch)

Biota Pharmaceuticals Announces Changes to Management and Board of Directors
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced a number of changes to management and its board of directors that will become effective October 1, 2014.
BOTA: 2.26 (unch)

Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Year-End 2014 Financial Results on September 26, 2014
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that it will host a conference call on Friday, September 26, 2014 at 9:00 a.m. EDT to review the Company's fourth quarter and year-end 2014 financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.
BOTA: 2.26 (unch)

Biota to Present Preclinical Data on RSV Compound BTA-C585 at ICAAC Meeting
GlobeNewswire - Thu Sep 04, 3:35PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will present a poster describing preclinical data on BTA-C585, the Company's oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections (RSV), at the 54 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in Washington, DC.
BOTA: 2.26 (unch)

BIOTA ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Biota Pharmaceuticals, Inc.
Business Wire - Fri Aug 01, 8:38AM CDT
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Biota Pharmaceuticals, Inc, (Nasdaq: BOTA) violated state or federal laws. Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products.
BOTA: 2.26 (unch)

Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate
GlobeNewswire - Fri Aug 01, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced top-line data from a randomized, double-blind, placebo-controlled, parallel-arm Phase 2 clinical trial comparing the safety and efficacy of a 40 mg and 80 mg dose of laninamivir octanoate ("LANI" to placebo. The trial, referred to as IGLOO, enrolled 639 patients across 12 countries in the Northern and Southern Hemisphere from June 2013 to April 2014. Of the 639 patients enrolled, 248, or 39%, had PCR confirmed influenza A or B virus and were included in the intent-to-treat efficacy analyses. Approximately 75% and 19% of the influenza-confirmed patients were infected with influenza A H1N1 2009 and H3N2, respectively, with 6% being infected with influenza B.
BOTA: 2.26 (unch)

3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
HALO: 9.34 (+0.31), BOTA: 2.26 (unch), ARIA: 6.81 (+0.15)

5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 11, 5:46AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
MPET: 0.92 (+0.02), BOTA: 2.26 (unch), WTSL: 0.06 (-0.02), PRAN: 1.74 (-0.02), WAVX: 0.83 (+0.02), NIHD: 0.06 (-0.01)

JOSEPH M. PATTI of Biota Pharmaceuticals, Inc. (BOTA)-NasdaqGS bought Shares of BOTA
M2 - Thu Jul 03, 9:38AM CDT
Reported by InsiderCow.com at 2014-07-02 13:00:06 ET
BOTA: 2.26 (unch)

Rhinovirus Infection - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rd8bmd/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Rhinovirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhinovirus Infection and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rhinovirus Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rhinovirus Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Alios BioPharma, Inc. - Cocrystal Pharma, Inc. - Sealife PHARMA GMBH - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rd8bmd/rhinovirus
BOTA: 2.26 (unch)

Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlldl7/complicated) has announced the addition of the "Complicated Intra-Abdominal Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Intra-Abdominal Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Intra-Abdominal Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Intra-Abdominal Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Intra-Abdominal Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - MerLion Pharmaceuticals Pte Ltd - Atox Bio Inc. - Tetraphase Pharmaceuticals Inc. - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/ql...omplicated
TTPH: 38.86 (+0.53), CBSTZ: 0.06 (+0.01), BOTA: 2.26 (unch), MRK: 57.46 (+0.25), AZN: 70.44 (+0.26)

Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of the over-allotment option increases the net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $23.3 million to approximately $26.9 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
BOTA: 2.26 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 46

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 97

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 60

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 57

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

Natural Food Color Industry Expected to Thrive by 2035

Updated Category News Views 167

Revitalizing the Natural Food Colors Market The natural food colors market is poised for remarkable growth, projected to expand from USD 2.01 billion to USD 4.03 billion by 2035. Market analysts suggest this surge will take place at a Compound Annual Growth Rate (CAGR) of 7.8%. This transformation is largely attributed to a shift in consumer preferences, regulatory...

Continue Reading
Fang Holdings Strengthens Leadership with Board Changes

Updated Category News Views 98

Fang Holdings Limited Announces Leadership Changes Fang Holdings Limited (OTC: SFUNY) has officially confirmed changes within its board of directors, marking an important phase for the company. As a prominent real estate Internet portal, Fang is committed to providing exceptional services to its users, and these changes in leadership are expected to support its strategic...

Continue Reading
NovaBridge's Visara Appoints Leaders to Propel Eye Treatment

Updated Category News Views 235

NovaBridge's Strategic Moves in Ophthalmology In a significant step forward for innovative treatment in ophthalmology, NovaBridge Biosciences (NASDAQ: NBP) has announced new appointments at its subsidiary, Visara, Inc. Cadmus C. Rich, MD, MBA, has been named Chief Medical Officer, while Carlos Quezada-Ruiz, MD, FASRS, takes the role of Chair of the Scientific Advisory...

Continue Reading
Celebrating Excellence: The Grossman Group's 25-Year Journey

Updated Category News Views 274

The Grossman Group Celebrates 25 Years of Communication Excellence In a prestigious recognition, The Grossman Group has earned the title of Best Small Agency at the Public Relations Society of America's 2025 Silver Anvil Awards. This honor comes during a significant milestone—the company's 25th anniversary—marked by years of dedication to enhancing internal...

Continue Reading
GiGi's Playhouse Celebrates the Opening of Its 61st Center in the Northwest

Updated Category News Views 360

GiGi's Playhouse unveiled its 61st Achievement Center back in the fall of a recent year, pushing forward its mission to uplift individuals impacted by Down syndrome. The grand opening of this center wasn’t just another launch—it was a culmination of seven years filled with passion, community spirit, and unwavering dedication from parents who aimed to create a haven...

Continue Reading